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ABSTRACT 
The objective of this research work was to formulate and optimize the floating drug delivery system 
containing cephalexin using 2
3 factorial design. Floating tablets were prepared by direct compression 
method incorporating HPMC K4M, xanthan gum, guar gum, sodium bicarbonate and tartaric acid as 
gas generating agent. The influence of independent variables like, polymer: polymer ratio, polymer 
type and tartaric acid on floating lag time and cephalexin release profile were studied. The diffusion 
exponent (n) of Krosmeyer Peppas for optimized formulation was found to be 0.635 which indicates 
the mechanism of drug release was anomalous transport. Floating lag time of optimized formulation 
was 1.50 min and remained buoyant for 24 hrs. Optimized formulation was checked for stability at 
40ºC / 75% RH which was found to be stable. Scanning electron microscopy study revealed gel 
formation. FT-IR studies revealed that there was no chemical interaction between cephalexin and other 
excipients. 
 
KEYWORDS: Floating drug delivery systems (FDDS), 2
3 factorial design, cephalexin (CFL), Fourier 
Transform Infrared Spectroscopy (FT-IR) and Scanning electron microscopy (SEM). 
 
INTRODUCTION 
The need for gastroretentive dosage forms (GRDFs) has led to extensive efforts in both academia and 
industry towards the development of such drug delivery systems
1. Prolonging the gastric residence of a 
dosage form may be of therapeutic value. Amongst the methods available to achieve this, floating 
dosage forms show considerable promise
2. 
The basic idea behind the development of such a system is to maintain a constant level of drug in the 
blood plasma in spite of the fact that the drug does not undergo disintegration. The drug usually keeps 
floating in the gastric fluid and slowly dissolves at a predetermined rate to release the drug from the 
dosage form and maintain constant drug levels in the blood
3.
Several approaches are used for the formulation of gastroretentive systems such as mucoadhesion
4, 5, 
flotation
6, sedimentation
7, 8, expansion
9, 10 and modified shape systems
11, 12. Both single-unit systems 
(tablets or capsules) and multiple-unit systems (multiparticulate systems) have been reported in the 
literature
13. Among these, FDDS offer the most effective and rational protection against early and 
random gastric emptying compared to the other methods proposed for prolonging the gastric residence 
time (GRT) of solid dosage forms
14. 
Extended-release dosage forms with prolonged residence time in the stomach are also highly desirable 
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for drugs that are locally active in the stomach and those are unstable in the intestinal or colonic 
environment or which have low solubility at higher pH values
15. FDDS has a lower density than 
gastric fluid and thus remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time
16. 
Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for 
drugs that are less soluble in a high pH environment. Effervescent floating dosage forms prepared with 
the help of swellable polymers such as methylcellulose and various effervescent compounds such as 
sodium bicarbonate, tartaric acid, and citric acid. They are formulated in such a way that when in 
contact with the acidic gastric contents, CO2 is liberated and gets entrapped in swollen hydrocolloids, 
which provides buoyancy to the dosage forms
17.
The objective of present work was to develop gastro retentive formulation, which releases drug in the 
stomach and upper gastrointestinal (GI) tract, and form an enhanced opportunity of absorption in the 
stomach and upper GI tract rather than the lower portions of the GI tract
18. 
Cephalexin (CFL) is chemically 7-[(amino-phenyl acetyl) amino]-3-methyl-8- oxo-5-thia-1-azabicyclo 
[4.2.0] oct-2-ene-2-carboxylic acid, belongs to the first generation cephalosporins, intended for oral 
administration. With the brand names of Ceporex (or Keflex) in the US, Novolexin in Canada, and 
many others outside North America, cephalexin is one of the top 20 drugs used in prescriptions 
worldwide. The first-generation cephalosporins have the highest activity against gram-positive and 
gram-negative bacterias.
19, 20
Figure 1:  Structure of Cephalexin 
 
Mechanism of action of CFL is same as that of beta-lactam antibiotics (such as penicillins). It acts by 
binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall and inhibits 
the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall 
autolytic enzymes such as autolysins; it is possible that it interferes with an autolysin inhibitor
21. CFL 
inhibits mucopeptide synthesis in bacterial cell wall, causing cell death
22. 
Oral therapy with CFL results in peak concentration in plasma of 16 µg/ml after a dose of 0.5 gm, this 
is adequate for the inhibition of many gm + ve and gm – ve pathogens.  It is well absorbed from the GI 
tract. The drug is not metabolized and 70-100% is excreted in the urine
23. 
CFL is chosen as the model drug in this study because it has a very short half life 0.9 ± 0.18 hour and 
peak concentration of 28±6.4 mg/ml.
3 And also degrading rapidly in basic media and remaining stable 
under mild acidic conditions makes CFL as suitable candidate for formulation into floating dosage 
form in order to prolong the GRT. No loss in its activity occurred in 72 hours at 25
0 C in the pH range 
of 3 to 5. The rate of degradation found at pH 6-7 (25
0C) was approximately 3% and 18% per day, 
respectively. In U.S.P hydrochloric acid buffer (pH 1.2), CFL lost 5% activity in 24 hours at 37
0 C as 
compared to 45% loss in phosphate buffer at pH 6.5 
24. 
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1. Materials and Methods 
1.1 Materials 
Cephalexin was obtained as a gift sample from Karnataka antibiotics and pharmaceuticals limited 
(KAPL), Bangalore, India. Polymers like HPMCK4M, xanthan gum, guar gum, tartaric acid were 
obtained as gift samples from Karnataka antibiotics and pharmaceuticals limited, Bangalore. All other 
chemicals used in the study were of analytical grade. 
1.2 Experimental design 
Factorial design is an experimental design technique, from which the factor involved and its relative 
importance can be assessed. In the present study a 2
3 factorial design was employed, containing 3 
factors evaluated at 2 levels (Table 1). The experimental trials were performed at all 8 possible 
combinations and the three independent formulation variables evaluated were: 
A = Polymer: polymer ratio 
B = Polymer type (xanthan gum/guar gum) 
C = Tartaric acid 
The response variables tested were: 
R1 = Floating lag time 
R2 = First hour drug release 
R3 = % Drug release at 12hr and 
R4 = Diffusion exponent (n) 
Table 1: Level of formulation variables 
Independent variables 
Coded 
values 
Polymer: Polymer ratio (A) 
HPMC K4M: xanthan/guar gum 
 
Polymer type 
(B) 
Tartaric acid 
(C) 
1 
-1 
4:1 
1:1 
Xanthan gum 
Guar gum 
20 
0 
*HPMC indicates hydroxyl propyl methyl cellulose 
1.3 Preparation of floating tablet: 
Floating tablets of CFL were prepared using HPMC K4M as swellable polymer, natural gums like 
xanthan gum/guar gum, sodium bicarbonate (NaHCO3) and tartaric acid as gas generating agent and 
dicalcium phosphate (DCP) as diluent, magnesium stearate as lubricant and talc as glidant. 
The drug and excipients were passed through sieve no. 44 (mesh aperture size 355 ± 13µm) prior to 
the preparation of the dosage form .The entire ingredients were weighed separately and mixed 
thoroughly for 10 minutes to ensure uniform mixing in geometrical ratio. The tablets were prepared by 
direct compression technique using 13 mm punch in 16-station rotary machine; Elit Jemkay engineers 
Pvt Ltd, Ahmedabad. 
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F =   X 100 
1.4 Sample Analysis: 
CFL was analyzed by ultraviolet (UV) spectrophotometric method at λmax 263 nm. The content of CFL 
in the formulation analyzed by dissolving in distilled water and was suitably diluted to give final 
concentrations of 5 to 50 µg/ml. The absorbance of sample was measured at 263 nm against distilled 
water as a blank.
25
2 EVALUATION PARAMETERS 
2.1 Flow properties 
The tablet blend were evaluated for their bulk density, tapped density, compressibility index and flow 
properties. The tapping method was used to determine the bulk density, tapped density and percent 
compressibility index. 
Compressibility index = [ρt-ρb / ρt] ×100 
Where ρt = tapped density  
ρb = initial bulk density of tablet blend.  
Angle of repose θ of the tablet blend measures the resistance to particle flow and was determined by 
fixed funnel method. 
2.2 Thickness and diameter:  
Control of physical dimensions of the tablet such as thickness and diameter is essential for consumer 
acceptance and tablet uniformity. The thickness and diameter of the tablet was measured in mm using 
Vernier Calipers.  
2.3 Hardness: 
The Monsanto hardness tester was used to determine the tablet hardness .The tablet was held between 
affixed and moving jaw. Scale was adjusted to zero; load was gradually increased until the tablet 
fractured. The value of the load at that point gives a measure of the hardness of the tablet which was 
expressed in kg/cm
2. 
2.4 Friability: 
Tablet strength was tested by Roche friabilator. Pre weighed tablets were allowed for 100 revolutions 
in 4 min and were dedusted. The percentage weight loss was calculated by reweighing the tablets. The 
% friability was then calculated by: -  
                                                               (Winitial) - (Wfinal)   
                                                            (Winitial)   
 2.5 Weight variation: 
Randomly selected 20 tablets were weighed individually and together in a single pan balance. The 
average weight was noted and standard deviation was calculated. The tablet passes the test if not more 
than two tablets fall outside the percentage limit and none of the tablet differs by more than double 
percentage limit. IP limit for weight variation in case of tablets weighting up to 120 mg is ± 10%, 120 
mg to 300 mg is ± 7.5% and more than 300 mg is ± 5%. 
PD= (Wavg) – (W initial) / (W avg) x 100 
 
Where PD= Percentage deviation,  
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Wavg =Average weight of tablet,  
Winitial =Individual weight of tablet. 
2.6 In vitro buoyancy study:  
The in vitro buoyancy was characterized by floating lag time and floating duration. The test was 
performed using USP type II paddle type apparatus using 900 ml of 0.1 N HCl at paddle rotation of 50 
rpm at 37±0.5
0. The floating lag time (time period between placing the tablet in the dissolution 
medium and tablet floating) and floating duration of the tablets were determined by visual observation. 
2.7 In vitro release testing: 
In vitro drug release of the formulation was carried out by USP type II basket type apparatus with 
rotating speed of 50 rpm and at temperature of 37±0.5
0 C. The dissolution medium used was 0.1N HCl 
(pH 1.2). The samples were withdrawn at predetermined time intervals for period of 12 hrs and 
replaced with the fresh medium, suitably diluted and were analyzed using UV/Visible 
spectrophotometer (Shimadzu Corporation, UV-1601, Japan). The test was performed in triplicate.  
2.8 Statistical analysis:  
The effect of formulation variables on the response variables were statically evaluated by applying 
one-way ANOVA at 0.05 level, using the commercially available software package Design-Expert®, 
version 7.1.5 (Stat- Ease, Inc.). The design was evaluated using a linear model, which bears following 
equation.  
R = b0 + b1 A + b2 B + b3 C 
Where R is the response variable, b0 the constant and b1, b2, b3 is the regression coefficient. A, B and C 
represent the main effect 
2.9 Fourier Transform Infrared Spectroscopy: 
IR spectroscopy was carried out for the following a) pure drug CFL, b) CFL with HPMC K4M, c) 
CFL with xanthan gum, d) CFL with NaHCO3, e) CFL with tartaric acid, f) CFL with DCP, g) CFL 
with talc and h) CFL with magnesium stearate using Shimadzu FTIR model 8300 by taking KBr disc. 
2.10 Scanning electron microscopy (SEM): 
The surface morphology of tablet membrane film of optimized formulation was examined before and 
after dissolution using scanning electron microscope. The samples were fixed on a brass stub using 
double-sided tape and then gold coated in vacuum by a sputter coater. The pictures were taken at 
excitation voltage of 20 KV. JSM-840A scanning Microscope; Jeol-Japan with JFC-1100E ion 
sputtering device was used. 
2.11 Stability Studies  
Accelerated stability studies were carried out as per ICH guidelines. The tablets were stored at 
different storage conditions at elevated temperature 40
0C/±/2
0C/75%± /5% RH for 6 months. The 
samples were withdrawn at monthly intervals and checked for physical appearance, drug content, 
floating properties and in vitro drug release studies. 
 
3 RESULTS AND DISCUSSION 
3.1 Design of experiment Formulation development: 
The formulations were designed  using 2
3 level Factorial design, the materials and compositions used 
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are presented in (Table 2). In this study, the effect of formulation variables- polymer: polymer ratio, 
polymer type and tartaric acid were chosen as independent variables. The dependent (response) 
variables included were floating lag time, first hour drug release, % drug release at 12 hr and diffusion 
exponent (n) (Table 3). For the generation of factorial models, only coefficients found to be significant 
(p<0.05) were used. 
Table 2: Material and Composition of floating tablets 
 
    Formulation Code 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
cephalexin  250  250  250  250  250  250  250  250 
HPMC K4M  125  200  200  200  125  125  200  125 
Xanthan gum  125  50  50  -  -  -  -  125 
Guar gum  -  -  -  50  125  125  50  - 
Tartaric acid  0  0  20  0  20  0  20  20 
Note: All the quantities are expressed in terms of milligrams. Each formulation contains 40 mg of 
sodium bicarbonate, 1% of magnesium stearate, 1% of talc and quantity sufficient to 600 mg of di-
calcium phosphate. 
Table 3:  2
3 factorial design with corresponding responses for floating lag time, dissolution 
characteristics and diffusion exponent. 
Formulation 
code 
R1 
Floating lag 
time (min) 
R2 
First hour drug 
release (%) 
R3 
% drug 
release at 12 
hour 
R4 
Diffusion 
 exponent (n) 
F1  7  18.22  91.71  0.62 
F2  5.12  19.6  93.75  0.6 
F3  2.62  18.4  96.75  0.64 
F4  22  15.98  82.6  0.65 
F5  55  13.88  83.31  0.68 
F6  56  14.46  80.7  0.69 
F7  20  16.28  84.68  0.63 
F8  6.2  17.61  91.85  0.63 
 
3.2 Flow property: 
The bulk density of the powder formulation was in the range of 0.27-0.34 gm/cc; the tapped density 
was in the range of 0.34-0.41 gm/cc, which indicates that the powder was not bulky. The angle of 
repose of the drug powder was in the range of 33.2
0-38.9
0, which indicate satisfactory flow of the 
powder, the Carr’s index was found to be in the range of 16-20, indicating compressibility of the tablet 
blend is fairly passable (Table 4). 
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Table 4: Data for blend evaluation 
 
3.3 Tablet thickness and diameter: 
The thickness of the tablet indicates that die fill was uniform. It depends upon the size of the punch 
(13 mm) and the weight of the tablet (600 mg). The thickness of the tablet was found to be 3.8-3.9 mm 
with diameter of 13± 0.1 mm. 
3.4 Hardness: Hardness was found to be 3.3-4.5 kg/cm
2 which have good mechanical strength. 
3.5 Friability: friability was found to be within the limits and was reported to be 0.5%. 
3.6 Weight variation: The average percentage deviation of 20 tablets of each formula was less than ± 
5 %, which provided good uniformity. (Table 5) 
Table 5: Data for tablet evaluation 
 
Evaluation parameters  Formulation 
code  Bulk density  Tapped density     Angle of  Carr’s Index 
F1  0.345  0.416  36.8  17.06 
F2  0.3106  0.3803  37.4  18.32 
F3  0.3064  0.3698  33.9  17.14 
F4  0.302  0.3684  35.7  18.02 
F5  0.2756  0.3408  36.4  19.13 
F6  0.3117  0.3887  38.9  19.80 
F7  0.3219  0.3909  35.4  17.65 
F8  0.3255  0.4012  34.6  18.86 
Evaluation parameters 
Formulation 
code  Thickness 
±S.D. (mm) 
Hardness± 
S.D.(kg/cm
2) 
Friability 
(%) 
Average weight 
variation 
F1  3.85 ± 0.043  3.5 ± 0.4  0.321  0.603 ± 0.011 
F2  3.7 ± 0.055  4.16 ± 0.2  0.233  0.600 ± 0.009 
F3  3.78 ± 0.085  4.23± 0.2  0.199  0.602 ± 0.010 
F4  3.75 ± 0.067  4.23± 0.1  0.352  0.601 ± 0.135 
F5  3.82 ± 0.054  3.93 ± 0.6  0.452  0.602 ± 0.008 
F6  3.79 ± 0.048  4.4 ± 0.3  0.244  0.601 ± 0.010 
F7  3.85 ± 0.028  3.6  ± 0.2  0.498  0.602 ± 0.008 
F8  3.88 ± 0.039  3.3 ± 0.3  0.545  0.599 ± 0.008 
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3.7 Optimization results: Optimized formula 
Optimized formula is drug 250 mg, HPMC K4M 200 mg, Xanthan gum 50 mg, Tartaric acid 19.68 
mg, Sodium bicarbonate 40 mg, DCP 28.32 mg, Magnesium stearate 1% and talc 1%. A numerical 
optimization technique by the desirability (0.9) approach was used to generate the optimum setting for 
the formulation. The optimized formulation was prepared and evaluated for the various responses. 
And the analysis of variance (ANOVA) information is shown in (Table 6). In vitro release profile was 
compared with USP limits as shown in the (Table 7). 
Table.6 Analysis of Variance for Dependent Variables from Factorial Design* 
Source  Sum of Squares  df  Mean square  F value  Probability 
Floating lag time                                      R
2= 0.8506 
Model  2877.98  3  959.33  7.59  0.0397 
A-A  693.04  1  693.04  5.48  0.0793 
B-B  2179.98  1  2179.98  17.24  0.0142 
C-C  4.96  1  4.96  0.039  0.8526 
Residual  505.65  4  126.41     
Cor Total  3383.63  7       
First hour drug release                                 R
2=0.9659 
Model  27.06  3  9.02  37.74  0.0022 
A-A  4.64  1  4.64  19.40  0.0117 
B-B  21.88  1  21.88  91.54  0.0007 
C-C  0.55  1  0.55  2.28  0.2052 
Residual  0.96  4  0.24     
Cor Total  28.02  7       
% drug release at 12hr                                 R
2=0.9838 
Model  249.35  3  83.12  81.11  0.0005 
A-A  13.03  1  13.03  12.72  0.0235 
B-B  228.66  1  228.66  7.48  0.0001 
C-C  7.66  1  7.66  223.13  0.0522 
Residual  4.10  4  1.02     
Cor Total  253.45  7       
Diffusion exponent (n)                                  R
2=0.7087 
Model  4.500E-003  3  1.500E-003  3.24  0.1427 
A-A  1.250E-003  1  1.250E-003  2.70  0.1755 
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B-B  3.200E-003  1  3.200E-003  6.92  0.0582 
C-C  6.350E-003  1  5.000E-005  0.11  0.7588 
Residual  1.850E-003  4  4.625E-004     
Cor Total  5.000E-005  7       
*Probability less than 0.05 indicate model terms are significant. 
Table 7: Comparison of release profile of controlled release tablets labeled for dosing every 12 hours 
with optimized formulation: 
Time (hours)  Amount dissolved (USP  Release profile of 
1  5  - 15   15.35 
2  12 - 30   27.85 
4  25 – 50   44.79 
8  55 - 75  67.12 
12  90 -100  97.14 
 
3.7.1 Floating lag time (R1)  
Among all the formulations, F2 and F3 formulations showed good floating properties with floating lag 
time of 5.12 min and 2.62 min respectively. This might be due to the presence of swellable polymer 
HPMC K4M and xanthan gum in 4:1 ratio and also due to the presence of gas generating agent. The 
gelling capacity of polymers also helps to float tablet by entrapping carbon dioxide gas. However the 
floating lag time of F5 and F6 formulation were found to be more (55 min) which might be due to the 
low levels of HPMC K4M and highly viscous guar gum. The floating lag time of optimized 
formulation was found to be 1.50 min and remained buoyant for 24hrs. 
R1= 38.04250-6.20500*A-16.50750*B-0.078750*C 
The linear model for R1  (floating lag time) found to be significant with F-value of  7.59 and P value 
0.0397. Values of "Prob > F" less than 0.0500 indicate model terms are significant. In this case, B is 
significant model term with P value of 0.0142. The factors A, B and C have an antagonistic effect on 
floating lag time. The effect of polymer: polymer ratio and polymer type on the floating lag time was 
found to be significant. Figure 5 represents the observed response values compared to that of predicted 
values. The effect of factors A, B and C can be further elucidated with the help of response surface 
plot (Figure 6). As the amount of HPMC K4M increased the floating lag time is decreased and it is 
lower in case of tablets prepared from xanthan gum than those prepared from guar gum. Results 
indicate that xanthan gum is superior to guar gum. 
Table 8: Comparison of experimented and predicted values of optimized formulation 
                   Dependable variables 
Optimized 
formulation  Floating lag 
time R1 
First hour drug 
release R2 
% drug release at 
12hr R3 
Diffusion 
exponent R4 
Pred.  2.6 min  18.5%  96.7%  0.630 
Exp.  1.50 min  15.35%  97.14%  0.635 
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3.7.2 First hour drug release R2: 
R2= +15.79625+0.50750*A+1.65375*B-0.026125*C 
When the HPMC K4M content is more, as the factor A increases from 1:1 to 4:1 the first hour drug 
release  increases which is desirable for an extended release formulation. In case of factor B (polymer 
type) xanthan gum shows synergistic effect than guargum.  
The linear model for R2  (first hour release) found to be significant with F-value of 37.74 and P value 
0.0022. In this case, A and B are significant model terms with P value of 0.0117and 0.0007 
respectively. The effect of factors A, B and C can be further elucidated with the help of response 
surface plot (Figure 7). In case of figure 7(a) high level of factor B (xanthan gum) gave high value of 
R2 at all levels of factor A and in case of figure 7(b) high level of factor A gave high value of R2 at all 
the levels of factor C which indicates that the factor A, polymer: polymer ratio and factor B (xanthan 
gum) have significant positive effect on first hour drug release.  
Figure 2: Dissolution profiles of the formulations 
 
Figure 3: Dissolution profiles of the formulations 
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3.7.3 % drug release at 12 hr R3: 
In this case, when the levels of all the 3 factors increases the percentage of durg release also increases 
i.e., the polymer:polymer ratio of 4:1, polymer type (xanthan gum) and high level of tartaric acid 
shows complete release of drug. The drug release profiles of all the formulations are given in the 
figure 2 and 3. 
R3= +85.06292+0.85083* A+5.34625* B+0.097875* C 
The linear model for R3  (% drug release at 12 hr) found to be significant with F-value of  81.11 and P 
value 0.0022. In this case A, B are significant model terms with P value of 0.0235 and 0.0001 
respectively. Figure 8 represents the observed response values compared to that of predicted values. 
The effect of factors A, B and C can be further elucidated with the help of response surface plot 
(Figure 9). The high level of factor B gave high value of R3 at all the levels of factor A where in case 
of figure 9(b), high level of factor B gave high value of R3 at all the levels of factor C which indicates 
that the factors A and B have significant positive effect on 12 hr drug release. Similar effect was 
observed in case R2. The factor B showed higher value indicating xanthan gum releases the drug at 
faster rate than guar gum.     
3.7.4 Diffusion exponent (n) R4: 
R4=  +0.66083-8.33333E-003 * A-0.020000* B+2.50000E-004* C 
The "Model F-value" of 3.24 implies the model is not significant. Data was analyzed by Krosmeyer 
Peppas plot. The ‘n’ value of optimized formulation was found to be 0.635 which was in the range of 
0.45<n<0.89 and K value 18.17. The diffusion exponent values indicate that the drug release follows 
non fickian transport.   
3.8 FT-IR spectroscopy  
The FT-IR studies revealed that CFL is compatible with the excipients used in the formulation. There 
were no extra peaks observed in the IR spectrum. The IR absorption band in cm
-1 of the drug and 
excipients was found to be similar. This established that the drug CFL and all the excipients used in 
the study showed no interaction and indicated that they were compatible with each other (Table 9). 
Table 9: FTIR studies of Cephalexin alone and with excipients 
Ars Pharm, Vol. 50 nº1; 8-23. B. Prakash Rao et al. Development of Gastro Retentive Drug Delivery System of Cephalexin 19 
FUNCTIONAL  α- NH2  β – lactam  Amide  -COOH  -COOH 
Standard CFL  2612.4  1759.9  1689.5  1592.1  1398.3 
CFL +HPMC K4M  2616  1758  1689.5  1594  1398.3 
CFL +Xanthan gum  2613  1759  1689.5  1596  1399.3 
CFL + NaHCO3 2609.5  1759.9  1689.5  1596  1398.3 
CFL + Tartaric acid  2613.4  1760.9  1689.5  1592.1  1397.3 
CFL + DCP  2610  1758  1689.5  1594  1395.4 
CFL + Talc  2612.4  1759.9  1689.5  1592.1  1397.3 
CFL +Magnesium     
stearate 
2612  1757  1689.5  1595  1399.3 
 
3.9 Scanning Electron Microscopy: SEM of the optimized formulation showed a well-uniformed gel 
structure which might be due to polymer relaxation upon absorption of water (Figure 4). 
Figure 4: Scanning electron microphotographs of optimized formulation: (A) –tablet at dry state, (B) 
– tablet after 8 hr swelling. 
   
                  (A)        (B) 
3.10 Stability Studies: Stability studies were  carried out as per ICH guidelines. The optimized 
formulation was found to be stable in terms of physical appearance, drug content, floating properties 
and in vitro drug release. 
Figure 5: correlation between actual and predicted values for floating lag time (R1) 
R1= FLOATING LAG TIME 
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Figure 6: Response surface plots showing the effect of polymers and tartaric acid on floating lag time 
R2= FIRST HOUR DRUG RELEASE 
 
 
                      (a)                                           (b) 
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Figure 7: Response surface plots showing the effect of polymers and tartaric acid on first hour drug 
release. 
R3= % DRUG RELEASE AT 12 HOUR 
 
                        (a)                                               (b) 
Figure 8: correlation between actual and predicted values for % drug  release at 12 hour (R3) 
 
Figure 9: Response surface plots showing the effect of polymers and tartaric acid on % drug release at 
12 hour. 
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                    (a)                                                (b) 
 
4. CONCLUSION 
Gastro-retentive drug delivery system was successfully prepared by using factorial design. It was 
found that sodium bicarbonate and tartaric acid have predominant effect on the floating lag time and is 
decreased with the increase in the ratio of HPMC K4M and xanthan gum and also xanthan gum 
showed increased drug release where as guar gum has retardant effect.  
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